BlackRock Trims Arcus Biosciences Stake to 9.0%
Ticker: RCUS · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1724521
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotech, stake-change
TL;DR
**BlackRock cut its Arcus Biosciences stake to 9.0%, a slight dip in institutional ownership.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, disclosing its ownership in Arcus Biosciences, Inc. as of December 31, 2023. This filing indicates BlackRock now beneficially owns 7,014,841 shares of Arcus Biosciences' Common Stock, representing 9.0% of the company. This is a decrease from their previous reported ownership, signaling a slight reduction in BlackRock's stake, which could be interpreted as a minor shift in institutional confidence for current or prospective investors.
Why It Matters
A major institutional investor like BlackRock reducing its stake, even slightly, can influence market sentiment and potentially signal a re-evaluation of the stock's future prospects.
Risk Assessment
Risk Level: low — The change in ownership is a minor adjustment by a large institutional investor and doesn't indicate a significant immediate risk to the company.
Analyst Insight
Investors should monitor future institutional filings for Arcus Biosciences to see if other major holders are also adjusting their positions, which could indicate a broader trend.
Key Numbers
- 7,014,841 — Shares Beneficially Owned (This is the total number of Arcus Biosciences shares BlackRock Inc. reported owning as of December 31, 2023.)
- 9.0% — Percentage of Class (This represents BlackRock Inc.'s ownership percentage of Arcus Biosciences' Common Stock as of December 31, 2023.)
- 03969F109 — CUSIP Number (This unique identifier helps identify Arcus Biosciences' Common Stock.)
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Arcus Biosciences, Inc. (company) — the subject company whose securities are being reported
- 7,014,841 (dollar_amount) — number of shares beneficially owned by BlackRock Inc.
- 9.0% (dollar_amount) — percentage of class beneficially owned by BlackRock Inc.
- December 31, 2023 (date) — date of event requiring the filing
- January 23, 2024 (date) — filing date of the SC 13G/A amendment
Forward-Looking Statements
- Arcus Biosciences' stock price may experience minor volatility due to the reported decrease in BlackRock's stake. (Arcus Biosciences) — medium confidence, target: next 1-2 weeks
- Other institutional investors might re-evaluate their positions in Arcus Biosciences following BlackRock's adjustment. (institutional investors) — low confidence, target: next quarter
FAQ
What is the purpose of this SC 13G/A filing by BlackRock Inc.?
This SC 13G/A is an amendment (Amendment No: 3) filed by BlackRock Inc. to update its beneficial ownership of Common Stock in Arcus Biosciences, Inc. as of December 31, 2023, under Rule 13d-1(b).
How many shares of Arcus Biosciences, Inc. Common Stock does BlackRock Inc. beneficially own according to this filing?
BlackRock Inc. beneficially owns 7,014,841 shares of Arcus Biosciences, Inc. Common Stock, as reported on the cover page of the filing.
What percentage of Arcus Biosciences, Inc.'s Common Stock does BlackRock Inc. now own?
BlackRock Inc. now owns 9.0% of the class of Arcus Biosciences, Inc.'s Common Stock, as stated on the cover page of the filing.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as indicated on the Schedule 13G form.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as designated by the 'X' in the appropriate box on the form.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Arcus Biosciences, Inc. (RCUS).